Tamoxifen is administered for estrogen receptor positive (ER+) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Here, ESR1 is linked to metabolic dysfunction-associated steatotic liver disease.